Compare FRBA & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRBA | FENC |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | 336 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.0M | 384.0M |
| IPO Year | N/A | 2010 |
| Metric | FRBA | FENC |
|---|---|---|
| Price | $17.32 | $10.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $20.00 | $17.67 |
| AVG Volume (30 Days) | 61.4K | ★ 160.4K |
| Earning Date | 10-22-2026 | 11-12-2026 |
| Dividend Yield | ★ 2.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | $1.31 | $62.55 |
| Revenue Next Year | $4.20 | $42.10 |
| P/E Ratio | ★ $9.71 | $178.33 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.41 | $5.65 |
| 52 Week High | $19.33 | $13.25 |
| Indicator | FRBA | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 33.05 | 43.64 |
| Support Level | $16.92 | $10.09 |
| Resistance Level | $17.19 | $11.29 |
| Average True Range (ATR) | 0.34 | 0.43 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 0.00 | 46.77 |
First Bank is a full-service commercial bank, with target businesses from individuals, businesses, and governmental entities located in service regions throughout New Jersey and eastern Pennsylvania, with a particular focus between New York City and Philadelphia. The group focuses on traditional deposit and loan products with businesses and individuals living and working in markets as the source of business. Its services are Business Banking, Personal Banking, Digital Banking, and Lending.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.